Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 3Unknown 2

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Neoplasm Metastasis 3Breast Neoplasms 3Triple Negative Breast Neoplasms 1Advanced Solid Tumors 1

Interventions

Trastuzumab 78Capecitabine 59Cyclophosphamide 54Paclitaxel 52Docetaxel 50Letrozole 44Fulvestrant 43Lapatinib 34Doxorubicin 31Carboplatin 31Vinorelbine 30Bevacizumab 29Anastrozole 28pembrolizumab 26exemestane 24Tamoxifen 23Gemcitabine 22Radiotherapy 21Albumin-Bound Paclitaxel 19Taxes 17Everolimus 17Epirubicin 15pertuzumab 13Ado-Trastuzumab Emtansine 13130-nm albumin-bound paclitaxel 13palbociclib 12Magnetic Resonance Spectroscopy 12liposomal doxorubicin 11atezolizumab 11Filgrastim 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Breast Neoplasms × tesetaxel × Clear all
NCT03326674 2021-07-30

CONTESSA

Odonate Therapeutics, Inc.

Phase 3 Terminated
685 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03858972 2021-07-30

CONTESSA 2

Odonate Therapeutics, Inc.

Phase 2 Terminated
152 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03952325 2021-07-30

CONTESSA TRIO

Odonate Therapeutics, Inc.

Phase 2 Terminated
294 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡